The 2015 ATA guidelines indicate that BRAF mutations, in combination with other gene mutations such as TERT, PIK3CA, and TP53, suggest a higher risk of malignancy in thyroid cancer, thus categorizing them as high-risk mutations [29]. The gene discussed is TP53; the disease is thyroid gland carcinoma.